On June 17, 2020 Phost’in Therapeutics (Montpellier France), a biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors, reported the appointments of Dr.Alain Herrera, MD,PhD as Chief Medical Officer and Pr. Bernard Pau, PhD, as Chief Operating Officer (Press release, Phost’in, JUN 17, 2020, View Source [SID1234561178]). Pr. Bernard Pau will also serve as Chairman of the Board.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Phost’in Therapeutics has previously announced in April 2020 that it has successfully secured a €10.3 million Series A round, from an international syndicate of Life Science and Innovation Investor led by Remiges Ventures to advance the clinical development of Phost’in’s main program, PhOx430, and to enhance capacity of its discovery platform.
Dr. Alain Herrera, MD, PhD has headed for ten years the Oncology business at Sanofi (1998-2008) where he was successively Vice President responsible for Global Oncology Business Strategy and Development and Head of Global Oncology Franchise and contributed to the worldwide registration of oxaliplatin (ELOXATIN) and rasburicase(FASTURTEC/ELITEK) as well as the Gastric and Head & Neck indications for docetaxel (TAXOTERE). Since 2008, he has worked with several companies in Europe, US and Asia being primarily involved in clinical development strategy, pipeline evaluation,product launch and positioning, partnerships. He is also an independent member of several Supervisory Boards/Boards of Directors including Nanobiotix, IDDI, GR-Transfert, AVEC Foundation. His previous responsibilities within Pharmaceutical industry include the roles of Chairman of Chiron Therapeutics Europe, Director of Chiron B.V, Corporate Vice President and Member of Management Council of Chiron Corporation and Managing Director at Pierre Fabre Oncology Laboratories. Besides these duties, Dr. Herrera hasalso been since 1991 Hematologist Consultant at Antoine Beclere Hospital. He has published and lectured extensively as an invited speaker at national and international meetings on cancers, and has authored a lot of original manuscripts in addition to contributing to numerous review articles and book chapters. He is an active member of ASCO (American Society of Clinical Oncology) and ESMO (Free ESMO Whitepaper) (European Society of Medical Oncology).
Dr.Alain HERRERA, who has been counseling Phost’in Therapeutics for the past 3 years to anticipate the clinical development of its main program PhOx430, a First-In-Class N-glycosylation inhibitor for the treatment of aggressive solid tumors, will be the company’s first CMO.
"I’m very excited about the promise of Phost’in Therapeutics pipeline, targeting aberrant Nglycosylation mecanisms"said Dr. Herrera. "As CMO, I really look forward to bringing PhOx430 into clinical trials for the full benefit ofpatients suffering of rare and aggressive tumors."
Pr. Bernard Pau,former student of the Institut Pasteur and Honorary Professor of immunology and biotechnology at the Universitybof Montpellier, has pioneered in France the industry transfer of innovation by bridging the gap between academic research and industry. His 30 years fruitful experience as a scientific manager and entrepreneur has been covering the fields of drug discovery, diagnostic tests and biotechnology.Afte r starting in industry, in Sanofi were he was Head of the Immunodiagnostics Department, he has built a brilliant career as a researcher and academic, constantly advocating for his "tripod": training,innovative research and economic partnerships. Thus, he directed a mixed research unit associating the CNRS, the university and the Bio-Rad group, participated in the creation of several pharmaceutical innovative companies(Innodia, Biodol Therapeutics, Kinnov Therapeutics, iMAb, …),and was appointed by French government as director of the CNRS Life science Department from 2002 to 2004. Pr.Bernard Pau co-authored more than150 international papers and patents.
"I am incredibly honored to have the opportunity to serve as COO of Phost’in Therapeutics" Bernard Pau stated. "Phost’in Therapeutics is committed to challenging the treatment of life threatening diseases, by using its innovative platform ofresources in Glyco-Immuno-Oncology, and I hope to be a valued resource the company can rely on."
Pr.Pau will also serve as Chairman of the Board.With the addition of Pr. Pau, Phost’in’s Board of Directors consists of five members, including Karine Chorro and Dr. Luvovic Clarion, co-founders and respectively CEO and CSO, Hitoshi Ono of Remiges Ventures, and Richard J. Meadows who both joined in April 2020, following the Series A completion. One of the 201 top ten Life Science Investors in North America according to Forbes Magazine, Richard Meadows was Co-Founder of and Managing Partner at CTI Life Sciences Fund and Partner at the Biotechnology Group of CDP Capital Technology Ventures.